References
- Quintana RA, Banchs J, Gupta R, Lin HY, Raj SD, Conley A, et al. Early evidence of cardiotoxicity and tumor response in patients with sarcomas after high cumulative dose Doxorubicin given as a continuous infusion. Sarcoma 2017; 2017: 7495914. doi: 10.1155/2017/7495914
- Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 2011; 377: 127-38. doi: 10.1016/S0140-6736(10)62231-3
- Jones RL, Wagner AJ, Kawai A, Tamura K, Shahir A, Van Tine BA, et al. Prospective evaluation of doxorubicin cardiotoxicity in patients with advanced soft-tissue sarcoma treated in the ANNOUNCE phase III randomized trial. Clin Cancer Res 2021; 27: 3861-6. doi: 10.1158/1078-0432.CCR-20-4592
- Krone RJ, Van Tine BA. More data to support a cardiac-oncologic partnership. JACC CardioOncol 2023; 5: 128-30. doi: 10.1016/j.jaccao.2023.01.002
- Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97: 2869-79. doi: 10.1002/cncr.11407
- Mo Z, Deng Y, Bao Y, Liu J, Jiang Y. Evaluation of cardiotoxicity of anthracycline-containing chemotherapy regimens in patients with bone and soft tissue sarcomas: a study of the FDA adverse event reporting system joint single-center real-world experience. Cancer Med 2023; 12: 21709-24. doi: 10.1002/cam4.6730
- Paulides M, Kremers A, Stohr W, Bielack S, Jurgens H, Treuner J, et al. Prospective longitudinal evaluation of doxorubicin-induced cardiomyopathy in sarcoma patients: a report of the late effects surveillance system (LESS). Pediatr Blood Cancer 2006; 46: 489-95. doi: 10.1002/pbc.20492
- Shamai S, Rozenbaum Z, Merimsky O, Derakhshesh M, Moshkovits Y, Arnold J, et al. Cardio-toxicity among patients with sarcoma: a cardio-oncology registry. BMC Cancer 2020; 20: 609. doi: 10.1186/s12885-020-07104-9
- Mitani I, Jain D, Joska TM, Burtness B, Zaret BL. Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. J Nucl Cardiol 2003; 10: 132-9. doi: 10.1067/mnc.2003.7
- Altena R, Perik PJ, van Veldhuisen DJ, de Vries EG, Gietema JA. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol 2009; 10: 391-9. doi: 10.1016/S1470-2045(09)70042-7
- Bonita R, Pradhan R. Cardiovascular toxicities of cancer chemotherapy. Semin Oncol 2013; 40: 156-67. doi: 10.1053/j.seminoncol.2013.01.004
- Khawaja MZ, Cafferkey C, Rajani R, Redwood S, Cunningham D. Cardiac complications and manifestations of chemotherapy for cancer. Heart 2014; 100: 1133-40. doi: 10.1136/heartjnl-2013-303713
- Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004; 109: 3122-31. doi: 10.1161/01. CIR.0000133187.74800.B9
- Alvarez JA, Russell RR. Cardio-oncology: the nuclear option. Curr Cardiol Rep 2017; 19: 31. doi: 10.1007/s11886-017-0844-z
- Al-Batran SE, Meerpohl HG, von Minckwitz G, Atmaca A, Kleeberg U, Harbeck N, et al. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer. Oncology 2006; 70: 141-6. doi: 10.1159/000093005
- Alhaja M, Chen S, Chin AC, Schulte B, Legasto CS. Cardiac safety of pegylated liposomal doxorubicin after conventional doxorubicin exposure in patients with sarcoma and breast cancer. Cureus 2023; 15: e44837. doi: 10.7759/cureus.44837
- Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V, Cruz-Flores S, et al. Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the american heart association. Circulation 2018; 137: e30-e66. doi: 10.1161/CIR.0000000000000556
- Shantakumar S, Olsen M, Vo TT, Norgaard M, Pedersen L. Cardiac dysfunction among soft tissue sarcoma patients in Denmark. Clin Epidemiol 2016; 8: 53-9. doi: 10.2147/CLEP.S100779
- Ettinghausen SE, Bonow RO, Palmeri ST, Seipp CA, Steinberg SM, White DE, et al. Prospective study of cardiomyopathy induced by adjuvant doxorubicin therapy in patients with soft-tissue sarcomas. Arch Surg 1986; 121: 1445-51. doi: 10.1001/archsurg.1986.01400120095016
- Cardinale D, Iacopo F, Cipolla CM. Cardiotoxicity of anthracyclines. Front Cardiovasc Med 2020; 7: 26. doi: 10.3389/fcvm.2020.00026
- Leger K, Slone T, Lemler M, Leonard D, Cochran C, Bowman WP, et al. Subclinical cardiotoxicity in childhood cancer survivors exposed to very low dose anthracycline therapy. Pediatr Blood Cancer 2015; 62: 123-7. doi: 10.1002/pbc.25206
- Alpman MS, Jarting A, Magnusson K, Manouras A, Henter JI, Broberg AM, et al. Longitudinal strain analysis for assessment of early cardiotoxicity during anthracycline treatment in childhood sarcoma: a single center experience. Cancer Rep (Hoboken) 2023; 6: e1852. doi: 10.1002/cnr2.1852
- Heemelaar JC, Speetjens FM, Al Jaff AAM, Evenhuis RE, Polomski EAS, Mertens BJA, et al. Impact of age at diagnosis on cardiotoxicity in high-grade osteosarcoma and Ewing sarcoma patients. JACC CardioOncol 2023; 5: 117-27. doi: 10.1016/j.jaccao.2022.11.016
- Tian Z, Yang Y, Yang Y, Zhang F, Li P, Wang J, et al. High cumulative doxorubicin dose for advanced soft tissue sarcoma. BMC Cancer 2020; 20: 1139. doi: 10.1186/s12885-020-07663-x
- Ehrhardt MJ, Leerink JM, Mulder RL, Mavinkurve-Groothuis A, Kok W, Nohria A, et al. Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 2023; 24: e108-e20. doi: 10.1016/S1470-2045(23)00012-8
- Yoon GJ, Telli ML, Kao DP, Matsuda KY, Carlson RW, Witteles RM. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally? J Am Coll Cardiol 2010; 56: 1644-50. doi: 10.1016/j.jacc.2010.07.023
- Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2014; 27: 911-39. doi: 10.1016/j.echo.2014.07.012
- Celutkiene J, Pudil R, Lopez-Fernandez T, Grapsa J, Nihoyannopoulos P, Bergler-Klein J, et al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J Heart Fail 2020; 22: 1504-24. doi: 10.1002/ejhf.1957
- Oikonomou EK, Kokkinidis DG, Kampaktsis PN, Amir EA, Marwick TH, Gupta D, et al. Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis. JAMA Cardiol 2019; 4: 1007-18. doi: 10.1001/jamacardio.2019.2952
- Lyon AR, Lopez-Fernandez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022; 43: 4229-361. doi: 10.1093/eurheartj/ehac244
- Suerken CK, D’Agostino RB, Jr., Jordan JH, Melendez GC, Vasu S, Lamar ZS, et al. Simultaneous left ventricular volume and strain changes during chemotherapy associate with 2-year postchemotherapy measures of left ventricular ejection fraction. J Am Heart Assoc 2020; 9: e015400. doi: 10.1161/JAHA.119.015400
- Muehlberg F, Funk S, Zange L, von Knobelsdorff-Brenkenhoff F, Blaszczyk E, Schulz A, et al. Native myocardial T1 time can predict development of subsequent anthracycline-induced cardiomyopathy. ESC Heart Fail 2018; 5: 620-9. doi: 10.1002/ehf2.12277
- Jordan JH, Vasu S, Morgan TM, D’Agostino RB, Jr., Melendez GC, Hamilton CA, et al. Anthracycline-associated T1 mapping characteristics are elevated independent of the presence of cardiovascular comorbidities in cancer survivors. Circ Cardiovasc Imaging 2016; 9. doi: 10.1161/CIRCIMAGING.115.004325
- Neilan TG, Coelho-Filho OR, Shah RV, Feng JH, Pena-Herrera D, Mandry D, et al. Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy. Am J Cardiol 2013; 111: 717-22. doi: 10.1016/j.amjcard.2012.11.022
- Ibrahim EH, Stojanovska J, Hassanein A, Duvernoy C, Croisille P, Pop-Busui R, et al. Regional cardiac function analysis from tagged MRI images. Comparison of techniques: Harmonic-Phase (HARP) versus Sinusoidal-Modeling (SinMod) analysis. Magn Reson Imaging 2018; 54: 271-82. doi: 10.1016/j.mri.2018.05.008
- Ibrahim EH, Baruah D, Budde M, Rubenstein J, Frei A, Schlaak R, et al. Optimized cardiac functional MRI of small-animal models of cancer radiation therapy. Magn Reson Imaging 2020; 73: 130-7. doi: 10.1016/j. mri.2020.08.020
- Ibrahim EH, Baruah D, Croisille P, Stojanovska J, Rubenstein JC, Frei A, et al. Cardiac magnetic resonance for early detection of radiation therapyinduced cardiotoxicity in a small animal model. JACC CardioOncol 2021; 3: 113-30. doi: 10.1016/j.jaccao.2020.12.006
- Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002; 105: 539-42. doi: 10.1161/hc0402.102975